^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

LRP4 (LDL Receptor Related Protein 4)

i
Other names: LRP4, LDL Receptor Related Protein 4, MEGF7, LRP-4, SOST2, CLSS, Low-Density Lipoprotein Receptor-Related Protein 4, Multiple Epidermal Growth Factor-Like Domains 7, LRP10, Low Density Lipoprotein Receptor-Related Protein 4, KIAA0816, CMS17
Associations
16d
Quantitative proteomic analysis of pathological and physiological ovarian aging: model evaluation, molecular mechanisms, and identification of early biomarkers and therapeutic targets. (PubMed, J Ovarian Res)
This study confirmed the validity of the cyclophosphamide-busulfan induced mouse model of ovarian senescence, highlighted both the shared and distinct molecular mechanisms of physiological and pathological ovarian aging, and identified promising early biomarkers and therapeutic intervention targets.
Journal
|
GSTP1 (Glutathione S-transferase pi 1) • CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • LRP4 (LDL Receptor Related Protein 4)
|
cyclophosphamide • busulfan
1m
New P1 trial
|
IFIH1 (Interferon Induced With Helicase C Domain 1) • LRP4 (LDL Receptor Related Protein 4) • MPO (Myeloperoxidase)
2ms
Integrating bulk and single-cell transcriptome to identify novel gene markers for germinal center B cells (GCB) subtype of diffuse large B-cell lymphoma. (PubMed, Ann Hematol)
All three aforementioned genes may be associated with the responsiveness of malignant human B-cell Lines to R-CHOP therapeutic agents. These results demonstrated that 19-GPS signature was effective and might potentially assist in guiding the prognosis and treatment options for DLBCL.
Journal
|
LRP4 (LDL Receptor Related Protein 4)
|
Rituxan (rituximab)
3ms
Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now? (PubMed, Brain Sci)
The evolving landscape of gMG treatment reflects a shift toward immunopathology-based precision medicine. Better characterization of subtype-specific molecular signatures and immune dysfunctions is essential to guide clinical decision-making and improve outcomes for treatment-refractory patients.
Review • Journal
|
IL6 (Interleukin 6) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • LRP4 (LDL Receptor Related Protein 4)
4ms
The LRP4/YAP axis drives the radiation-tolerant persister (RTP) cell state in breast cancer. (PubMed, Theranostics)
We further demonstrate that overexpression of LRP4 is common in residual disease post-treatment and is associated with breast tumors of poor prognosis. This work has demonstrated that the LRP4/YAP axis drives radioresistance by promoting the emergence of RTP cells through radiation-induced plasticity, and that modulation of the LRP4/YAP axis is a promising strategy for sensitizing breast cancers to radiotherapy, opening up a new avenue for improving patient outcomes.
Journal
|
LRP4 (LDL Receptor Related Protein 4)
5ms
Autoantibodies in myasthenia gravis. (PubMed, Int Rev Neurobiol)
We review the evolution of diagnostic assays, from early RIA to modern CBA, and addresses interpretative pitfalls, particularly in borderline or "seronegative" cases. Finally, the authors address the significance of accurate autoantibody detection in the diagnosis and management of patients with one of the antibody MG subtypes, as well as in patients with other autoimmune conditions and thymic malignancies.
Review • Journal
|
LRP4 (LDL Receptor Related Protein 4)
6ms
Myasthenia gravis: Mechanisms, clinical syndromes, and diagnosis. (PubMed, Dis Mon)
Due to the variable presentation of symptoms, diagnosing MG can be challenging. A comprehensive approach that combines clinical assessment, serological testing, electrophysiological studies, and imaging is essential for accurate diagnosis.
Journal
|
LRP4 (LDL Receptor Related Protein 4)
6ms
Effective Use of BCMA-Targeting Bispecific T-Cell-Engaging Antibody in Treatment Refractory LRP4-positive Myasthenia Gravis. (PubMed, Mol Ther)
The patient regained mobility and has sustained remission during short-term follow-up. This case highlights the therapeutic potential of teclistamab and BCMA-targeting strategies in MG, warranting further investigation.
Journal
|
LRP4 (LDL Receptor Related Protein 4)
|
Tecvayli (teclistamab-cqyv)
6ms
A Multicenter Retrospective Study on Factors Influencing the Efficacy of Efgartigimod in the Treatment of Adult Generalized Myasthenia Gravis (ChiCTR2500101971)
P=N/A, N=60, Completed, Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University
New trial
|
TTN (Titin) • LRP4 (LDL Receptor Related Protein 4)
7ms
Periplocin targets LRP4 to regulate metabolic homeostasis and anti-inflammation for the treatment of IVDD. (PubMed, Phytomedicine)
Our research suggests that periplocin may serve as a promising treatment for IVDD, offering anti-inflammatory benefits, preventing ECM degradation, and promoting ECM anabolism.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • LDLR (Low Density Lipoprotein Receptor) • LRP4 (LDL Receptor Related Protein 4)
7ms
Alterations in Gene Expression Associated with Invasion of RAS-Mutant Thyroid Tumors and Their Potential Diagnostic and Therapeutic Utility. (PubMed, Eur Thyroid J)
Development of invasion in RAS-mutant tumors is associated with significant alteration in gene expression. Expression levels of 6 genes and nodule size may predict invasion in RAS-mutant thyroid nodules, whereas chemical inhibition of CA12 may have a potential therapeutic effect in RAS-mutant tumors.
Journal
|
RAS (Rat Sarcoma Virus) • CA12 (Carbonic Anhydrase 12) • LRP4 (LDL Receptor Related Protein 4)
|
RAS mutation
7ms
NLRP4 drives olaparib resistance in pancreatic cancer. (PubMed, Autophagy Rep)
Inhibition of either mitochondrial ROS production with MitoQ or autophagy with chloroquine (CQ) could sensitize pancreatic cancer cells to olaparib. These findings emphasize NLRP4's role in promoting both autophagy and DNA repair in response to olaparib, suggesting that patients with low NLRP4 expression might respond more favorably to olaparib treatment.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • LRP4 (LDL Receptor Related Protein 4)
|
Lynparza (olaparib) • chloroquine phosphate